These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34724588)

  • 21. Comparison of immunosuppressive therapies for IgA nephropathy after tonsillectomy: three-course versus one-course steroid pulse combined with mizoribine.
    Kaneko T; Arai M; Ikeda M; Morita M; Watanabe Y; Hirama A; Shimizu A; Tsuruoka S
    Int Urol Nephrol; 2015 Nov; 47(11):1823-30. PubMed ID: 26433884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical course of Immunoglobulin A nephropathy with crescents in a multi-ethnic Southeast Asian cohort.
    Lim CC; Baikunje S; Choo JCJ; Tan PH; Foo M; Woo KT
    Nephrology (Carlton); 2020 Sep; 25(9):708-713. PubMed ID: 32400945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IgA nephropathy with presentation of nephrotic syndrome at onset in children.
    Shima Y; Nakanishi K; Sato M; Hama T; Mukaiyama H; Togawa H; Tanaka R; Nozu K; Sako M; Iijima K; Suzuki H; Yoshikawa N
    Pediatr Nephrol; 2017 Mar; 32(3):457-465. PubMed ID: 27714465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.
    Rauen T; Fitzner C; Eitner F; Sommerer C; Zeier M; Otte B; Panzer U; Peters H; Benck U; Mertens PR; Kuhlmann U; Witzke O; Gross O; Vielhauer V; Mann JFE; Hilgers RD; Floege J
    J Am Soc Nephrol; 2018 Jan; 29(1):317-325. PubMed ID: 29042456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and histological differences between adults and children in new onset IgA nephropathy.
    Cambier A; Rabant M; El Karoui K; Peuchmaur M; Servais A; Hertig A; Deschenes G; Salomon R; Hogan J; Robert T
    Pediatr Nephrol; 2020 Oct; 35(10):1897-1905. PubMed ID: 32444925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria.
    Zhong Z; Tang Y; Tan J; Tan L; Pei G; Qin W
    Int Urol Nephrol; 2021 Jan; 53(1):121-127. PubMed ID: 32944888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S; Li JP
    Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis.
    Xu K; Zhang L; Ding J; Wang S; Su B; Xiao H; Wang F; Zhong X; Li Y
    J Nephrol; 2018 Apr; 31(2):279-286. PubMed ID: 29185209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A mixed-method evaluation of the relationship between Oxford classification scores and longitudinal changes in proteinuria in patients with immunoglobulin A nephropathy.
    Xu RC; Guo JY; Cao T; Xu Y; Liao Y; Chen YN; Song HY; Chen XJ; Guan MJ; Tang F; Xiang Q; Chen XL; Wan QJ
    Front Endocrinol (Lausanne); 2022; 13():890900. PubMed ID: 36704031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunosuppressant Agents as Add-On Therapy Failed to Improve the Outcome of Immunoglobulin A Nephropathy with Crescent Score C1.
    Bi X; Yu Y; Zhou S; Zhou Y; Zhao J; Xiong J
    Nephron; 2024; 148(9):587-600. PubMed ID: 38723614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C; Torres DD; Rossini M; Pesce F; Schena FP
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children.
    Kang Z; Li Z; Duan C; Wu T; Xun M; Ding Y; Zhang Y; Zhang L; Yin Y
    Pediatr Nephrol; 2015 Jul; 30(7):1121-9. PubMed ID: 25773534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection.
    Riispere Ž; Kuudeberg A; Seppet E; Sepp K; Ilmoja M; Luman M; Kõlvald K; Auerbach A; Ots-Rosenberg M
    BMC Nephrol; 2017 Mar; 18(1):89. PubMed ID: 28292274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunosuppressive agents for treating IgA nephropathy.
    Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN)].
    Nagy J; Sági B; Máté J; Vas T; Kovács T
    Orv Hetil; 2017 Dec; 158(49):1946-1952. PubMed ID: 29199436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical usefulness of the Oxford classification in determining immunosuppressive treatment in IgA nephropathy.
    Yoon CY; Chang TI; Kang EW; Lim BJ; Kie JH; Kee YK; Kim H; Park S; Yun HR; Jung SY; Jhee JH; Kwon YE; Oh HJ; Park JT; Yoo TH; Kang SW; Jeong HJ; Han SH
    Ann Med; 2017 May; 49(3):217-229. PubMed ID: 27764976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function.
    Moriyama T; Honda K; Nitta K; Yumura W; Nihei H
    Clin Exp Nephrol; 2004 Sep; 8(3):237-42. PubMed ID: 15480901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pro: STOP immunosuppression in IgA nephropathy?
    Pozzi C
    Nephrol Dial Transplant; 2016 Nov; 31(11):1766-1770. PubMed ID: 27515694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression.
    Chakera A; MacEwen C; Bellur SS; Chompuk LO; Lunn D; Roberts ISD
    J Nephrol; 2016 Jun; 29(3):367-375. PubMed ID: 26318019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of IgA nephropathy with renal insufficiency.
    Pozzi C; Sarcina C; Ferrario F
    J Nephrol; 2016 Aug; 29(4):551-8. PubMed ID: 26743078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.